FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003454094> ?p ?o ?g. }

• W2003454094 endingPage "388" @default.
• W2003454094 startingPage "383" @default.
• W2003454094 abstract "A high-throughput chemical screen reveals that harmine and its analogs promote improved human pancreatic beta cell replication and function, thus identifying these molecules as a potential new class of antidiabetic agents. Types 1 and 2 diabetes affect some 380 million people worldwide. Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells. Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (∼2%) engaged in the cell cycle in the first year of life1,2,3,4. In embryonic life and after early childhood, beta cell replication is barely detectable. Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts1,2,3,4,5,6,7,8. Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo. Here, using a high-throughput small-molecule screen (HTS), we find that analogs of the small molecule harmine function as a new class of human beta cell mitogenic compounds. We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation. Using three different mouse and human islet in vivo–based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control. These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy. Enhancing the potency and beta cell specificity of these compounds are important future challenges." @default.
• W2003454094 created "2016-06-24" @default.
• W2003454094 creator A5000214341 @default.
• W2003454094 creator A5003645638 @default.
• W2003454094 creator A5006140692 @default.
• W2003454094 creator A5007728747 @default.
• W2003454094 creator A5012806212 @default.
• W2003454094 creator A5019520558 @default.
• W2003454094 creator A5047201441 @default.
• W2003454094 creator A5049078993 @default.
• W2003454094 creator A5059949888 @default.
• W2003454094 creator A5074154164 @default.
• W2003454094 creator A5079417201 @default.
• W2003454094 date "2015-03-09" @default.
• W2003454094 modified "2023-10-18" @default.
• W2003454094 title "A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication" @default.
• W2003454094 cites W1596413280 @default.
• W2003454094 cites W1870041030 @default.
• W2003454094 cites W1957658076 @default.
• W2003454094 cites W1972250422 @default.
• W2003454094 cites W1975715157 @default.
• W2003454094 cites W1991001144 @default.
• W2003454094 cites W1994233243 @default.
• W2003454094 cites W2000040240 @default.
• W2003454094 cites W2002404925 @default.
• W2003454094 cites W2004466285 @default.
• W2003454094 cites W2011924190 @default.
• W2003454094 cites W2018186748 @default.
• W2003454094 cites W2019379291 @default.
• W2003454094 cites W2019904725 @default.
• W2003454094 cites W2031218764 @default.
• W2003454094 cites W2038809002 @default.
• W2003454094 cites W2043431165 @default.
• W2003454094 cites W2057319734 @default.
• W2003454094 cites W2060743272 @default.
• W2003454094 cites W2063247572 @default.
• W2003454094 cites W2069795464 @default.
• W2003454094 cites W2070186790 @default.
• W2003454094 cites W2073874786 @default.
• W2003454094 cites W2075232662 @default.
• W2003454094 cites W2078629831 @default.
• W2003454094 cites W2082044596 @default.
• W2003454094 cites W2105595222 @default.
• W2003454094 cites W2106099270 @default.
• W2003454094 cites W2107818841 @default.
• W2003454094 cites W2108975920 @default.
• W2003454094 cites W2113544353 @default.
• W2003454094 cites W2114055879 @default.
• W2003454094 cites W2115383202 @default.
• W2003454094 cites W2115474053 @default.
• W2003454094 cites W2124301111 @default.
• W2003454094 cites W2130155276 @default.
• W2003454094 cites W2134747485 @default.
• W2003454094 cites W2135732933 @default.
• W2003454094 cites W2137206981 @default.
• W2003454094 cites W2142464034 @default.
• W2003454094 cites W2143050701 @default.
• W2003454094 cites W2143935915 @default.
• W2003454094 cites W2145039418 @default.
• W2003454094 cites W2145743390 @default.
• W2003454094 cites W2147154230 @default.
• W2003454094 cites W2148147368 @default.
• W2003454094 cites W2153745698 @default.
• W2003454094 cites W2167977281 @default.
• W2003454094 cites W2168175722 @default.
• W2003454094 cites W2333335236 @default.
• W2003454094 cites W4230291211 @default.
• W2003454094 cites W4250627081 @default.
• W2003454094 doi "https://doi.org/10.1038/nm.3820" @default.
• W2003454094 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4690535" @default.
• W2003454094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25751815" @default.
• W2003454094 hasPublicationYear "2015" @default.
• W2003454094 type Work @default.
• W2003454094 sameAs 2003454094 @default.
• W2003454094 citedByCount "287" @default.
• W2003454094 countsByYear W20034540942015 @default.
• W2003454094 countsByYear W20034540942016 @default.
• W2003454094 countsByYear W20034540942017 @default.
• W2003454094 countsByYear W20034540942018 @default.
• W2003454094 countsByYear W20034540942019 @default.
• W2003454094 countsByYear W20034540942020 @default.
• W2003454094 countsByYear W20034540942021 @default.
• W2003454094 countsByYear W20034540942022 @default.
• W2003454094 countsByYear W20034540942023 @default.
• W2003454094 crossrefType "journal-article" @default.
• W2003454094 hasAuthorship W2003454094A5000214341 @default.
• W2003454094 hasAuthorship W2003454094A5003645638 @default.
• W2003454094 hasAuthorship W2003454094A5006140692 @default.
• W2003454094 hasAuthorship W2003454094A5007728747 @default.
• W2003454094 hasAuthorship W2003454094A5012806212 @default.
• W2003454094 hasAuthorship W2003454094A5019520558 @default.
• W2003454094 hasAuthorship W2003454094A5047201441 @default.
• W2003454094 hasAuthorship W2003454094A5049078993 @default.
• W2003454094 hasAuthorship W2003454094A5059949888 @default.
• W2003454094 hasAuthorship W2003454094A5074154164 @default.
• W2003454094 hasAuthorship W2003454094A5079417201 @default.
• W2003454094 hasBestOaLocation W20034540942 @default.
• W2003454094 hasConcept C104317684 @default.

• next